Mycophenolate mofetil in primary central nervous system vasculitis

Carlo Salvarani, Robert D Jr. Brown, Teresa J H Christianson, John III Huston, Caterina Giannini, Dylan V. Miller, Francesco Muratore, Gene G. Hunder

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalSeminars in Arthritis and Rheumatism
Volume45
Issue number1
DOIs
StatePublished - Aug 1 2015

Fingerprint

Central Nervous System Vasculitis
Mycophenolic Acid
Therapeutics
Leukopenia
Prednisone
Cyclophosphamide
Safety
Recurrence

Keywords

  • Mycophenolate mofetil
  • PCNSV
  • Therapy
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

Mycophenolate mofetil in primary central nervous system vasculitis. / Salvarani, Carlo; Brown, Robert D Jr.; Christianson, Teresa J H; Huston, John III; Giannini, Caterina; Miller, Dylan V.; Muratore, Francesco; Hunder, Gene G.

In: Seminars in Arthritis and Rheumatism, Vol. 45, No. 1, 01.08.2015, p. 55-59.

Research output: Contribution to journalArticle

Salvarani, Carlo ; Brown, Robert D Jr. ; Christianson, Teresa J H ; Huston, John III ; Giannini, Caterina ; Miller, Dylan V. ; Muratore, Francesco ; Hunder, Gene G. / Mycophenolate mofetil in primary central nervous system vasculitis. In: Seminars in Arthritis and Rheumatism. 2015 ; Vol. 45, No. 1. pp. 55-59.
@article{f64daf8735114c94b69ec76fb4ad33e5,
title = "Mycophenolate mofetil in primary central nervous system vasculitis",
abstract = "Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.",
keywords = "Mycophenolate mofetil, PCNSV, Therapy, Vasculitis",
author = "Carlo Salvarani and Brown, {Robert D Jr.} and Christianson, {Teresa J H} and Huston, {John III} and Caterina Giannini and Miller, {Dylan V.} and Francesco Muratore and Hunder, {Gene G.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.semarthrit.2015.02.008",
language = "English (US)",
volume = "45",
pages = "55--59",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Mycophenolate mofetil in primary central nervous system vasculitis

AU - Salvarani, Carlo

AU - Brown, Robert D Jr.

AU - Christianson, Teresa J H

AU - Huston, John III

AU - Giannini, Caterina

AU - Miller, Dylan V.

AU - Muratore, Francesco

AU - Hunder, Gene G.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

AB - Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

KW - Mycophenolate mofetil

KW - PCNSV

KW - Therapy

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84937737529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937737529&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2015.02.008

DO - 10.1016/j.semarthrit.2015.02.008

M3 - Article

C2 - 25800827

AN - SCOPUS:84937737529

VL - 45

SP - 55

EP - 59

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 1

ER -